EUVIMEDEUVIMED entdecken
Crossref

Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies

Ingrid A Franken iD, Georg Busslinger, Bas L A M Weusten, Lodewijk A A Brosens, Jelle P Ruurda, Nadia Haj Mohammad, Stella Mook, Hans Clevers, Richard Van Hillegersberg iD

Diseases of the Esophagus · 2026

DOI: 10.1093/dote/doaf115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, 2026. Verfasst von Ingrid A Franken und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Precision Medicine, Organoids, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upper gastrointestinal malignancies bear a high morbidity and mortality burden. Curative treatment requires a multimodal approach, subjecting patients to preoperative chemotherapy or chemoradiation to downstage the tumor before resection. Various preoperative regimens exist but there is no tailor-made approach based on the tumor sensitivity for the individual patient. This predisposes a considerable subset of patients to inadequate treatment and highlights the need for personalized medicine, for which the potential of patient-derived cancer organoids (PDCOs) was investigated. PDCOs were established from pre-treatment biopsies of two gastric and four esophageal cancer patients, and compared to previously established PDCOs derived from four gastric and two esophageal resections post-neoadjuvant treatment. PDCO sensitivity, defined as area under the dose–response curve, was determined to in vitro chemotherapy (epirubicin, oxaliplatin, capecitabine and 5-fluorouracil, leucovorin, oxaliplatin, docetaxel) and chemoradiation (carboplatin, paclitaxel, radiotherapy). The PDCOs were established from 55% of the pre-treatment biopsies (derived from four of six patients), and demonstrated differential sensitivity to the treatment screens. PDCOs initiated from pre-treatment tissue were more sensitive than those derived from post-treatment tissue. In addition, drug screen sensitivity of pre-treatment PDCOs correlated well with patient response in terms of tumor regression grade. The current results provide a proof of principle and offer recommendations for a structured pipeline to more efficiently establish, validate and screen a larger cohort of pre-treatment PDCOs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineOrganoidsEsophageal NeoplasmsStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedNeoadjuvant TherapyCapecitabineFluorouracilBiopsyOxaliplatinAntineoplastic Agents

Stichwörter der Autor:innen

cancer biomarkermodelneoadjuvant chemoradiationneoadjuvant chemotherapyprognosticupper gastrointestinal surgery

Substanzen

CapecitabineFluorouracilOxaliplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Organoid Laboratory, Hubrecht Institute, Utrecht, The Netherlands.
  • Department of Gastroenterology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Surgical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Ingrid A Franken, Richard Van Hillegersberg

Zitieren

APA

Franken, I. A., Busslinger, G., Weusten, B. L. A. M., Brosens, L. A. A., Ruurda, J. P., Haj Mohammad, N., Mook, S., Clevers, H., & Van Hillegersberg, R. (2026). Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf115

Vancouver

Franken IA, Busslinger G, Weusten BLAM, Brosens LAA, Ruurda JP, Haj Mohammad N, et al. Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies. Diseases of the Esophagus. 2026. doi:10.1093/dote/doaf115

BibTeX
@article{Franken2026,
  author = {Franken, Ingrid A and Busslinger, Georg and Weusten, Bas L A M and Brosens, Lodewijk A A and Ruurda, Jelle P and Haj Mohammad, Nadia and Mook, Stella and Clevers, Hans and Van Hillegersberg, Richard},
  title = {Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies},
  journal = {Diseases of the Esophagus},
  year = {2026},
  doi = {10.1093/dote/doaf115}
}
Kostenlos starten →